ArticleJournal of neuro-oncology2016

Adverse event grading following CTCAE v3.0 underestimates hypertensive side effects in patients with glioma treated with Bevacizumab.

Elisabeth Bumes et al.PubMed ↗Publisher ↗

No numbers read from the abstract.